December 13, 2019
US Merck’s immuno-oncology star Keytruda (pembrolizumab) looks almost certain to break the US$10 billion mark in its global sales this year, becoming the first immune checkpoint inhibitor to achieve the feat, buoyed by its stellar performance in the lucrative lung...read more